These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25064584)

  • 1. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice.
    Ussher JR; Fillmore N; Keung W; Mori J; Beker DL; Wagg CS; Jaswal JS; Lopaschuk GD
    Can J Cardiol; 2014 Aug; 30(8):940-4. PubMed ID: 25064584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD; Barr R; Thomas PD; Dyck JR
    Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
    Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.
    Ussher JR; Keung W; Fillmore N; Koves TR; Mori J; Zhang L; Lopaschuk DG; Ilkayeva OR; Wagg CS; Jaswal JS; Muoio DM; Lopaschuk GD
    J Pharmacol Exp Ther; 2014 Jun; 349(3):487-96. PubMed ID: 24700885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
    Wenmeng W; Qizhu T
    Med Hypotheses; 2011 Feb; 76(2):181-3. PubMed ID: 20932648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
    Onay-Besikci A; Guner S; Arioglu E; Ozakca I; Ozcelikay AT; Altan VM
    Can J Physiol Pharmacol; 2007 May; 85(5):527-35. PubMed ID: 17632588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of acetyl-CoA C-acyltransferase inhibitor trimetazidine on parameters of global and local systolic and diastolic functions of left ventricular myocardium in patients with combined postinfarction ischemic syndrome].
    Kastanaian AA; Nelasov NIu; Eroshenko OL; Kazarian NB; Drobotia NV
    Kardiologiia; 2003; 43(9):21-7. PubMed ID: 14593366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimetazidine in conditions other than coronary disease, old drug, new tricks?
    Zou H; Zhu XX; Ding YH; Jin QY; Qian LY; Huang DS; Cen XJ
    Int J Cardiol; 2017 May; 234():1-6. PubMed ID: 28256321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
    Sisakian AS; Torgomian AL; Barkhudarian AL
    Klin Med (Mosk); 2006; 84(10):55-8. PubMed ID: 17201276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimetazidine normalizes postischemic function of hypertrophied rat hearts.
    Saeedi R; Grist M; Wambolt RB; Bescond-Jacquet A; Lucien A; Allard MF
    J Pharmacol Exp Ther; 2005 Jul; 314(1):446-54. PubMed ID: 15840766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase.
    Fragasso G; Spoladore R; Cuko A; Palloshi A
    Curr Clin Pharmacol; 2007 Sep; 2(3):190-6. PubMed ID: 18690865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy.
    Sisakian H; Torgomyan A; Barkhudaryan A
    Acta Cardiol; 2007 Oct; 62(5):493-9. PubMed ID: 17982971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metabolic approach in diabetic patients with coronary artery disease.
    Fragasso G; Salerno A; Spoladore R; Cera M; Montanaro C; Margonato A
    Curr Pharm Des; 2009; 15(8):857-62. PubMed ID: 19275650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
    Lopaschuk GD
    Coron Artery Dis; 2001 Feb; 12 Suppl 1():S8-11. PubMed ID: 11286307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.
    Bucci M; Borra R; Någren K; Pärkkä JP; Del Ry S; Maggio R; Tuunanen H; Viljanen T; Cabiati M; Rigazio S; Taittonen M; Pagotto U; Parkkola R; Opie LH; Nuutila P; Knuuti J; Iozzo P
    Cardiovasc Ther; 2012 Dec; 30(6):333-41. PubMed ID: 21884010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
    Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure.
    Morgan EE; Young ME; McElfresh TA; Kung TA; Hoit BD; Chandler MP; Stanley WC
    Fundam Clin Pharmacol; 2006 Oct; 20(5):503-5. PubMed ID: 16968422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
    Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.